Mon, Dec 22, 2014, 9:41 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • efficient_frontier2002 efficient_frontier2002 Nov 16, 2012 12:10 AM Flag


    Dr. Bahcall stated that ganetespib could top $2 billion in annual sales as a combo therapy for 2nd line NSCLC. All it has to do is achieve 25% penetration (which he seemed to think was conservative) of the 160,000 patients/year and charge ~$50K.

    This doesn't include its monotherapy trials or combo with first line NSCLC or other cancers or its other pipeline drugs.

    He also stated that the Phase 3 trial was 99% powered assuming a 60% Hazard Ratio. The Phase 2b Interim Hazard Ratio was far better -- 37%! The probability of failure is truly microscopic.

    It's hard to see how Synta can fail. Lives will be extended by 170% (not 70%) (about a full year on average) if the Phase 2b Interim results hold up. And they could get even better since the trend has been improving with time.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.74-0.06(-2.14%)Dec 22 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gilead Sciences Inc.
NASDAQMon, Dec 22, 2014 4:00 PM EST
Ocwen Financial Corp.
NYSEMon, Dec 22, 2014 4:00 PM EST